282 related articles for article (PubMed ID: 32660456)
21. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
[TBL] [Abstract][Full Text] [Related]
22. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Lightfoot AJ; Breyer BN; Rosevear HM; Erickson BA; Konety BR; O'Donnell MA
Urol Oncol; 2014 Jan; 32(1):35.e15-9. PubMed ID: 23510863
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
[TBL] [Abstract][Full Text] [Related]
24. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Riedl C
World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
[TBL] [Abstract][Full Text] [Related]
25. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
26. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
27. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Pareek T; Parmar K; Sharma AP; Kumar S
Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025
[TBL] [Abstract][Full Text] [Related]
28. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
29. [Intravesical therapy with mitomycin through electromotive drug administration].
Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
[TBL] [Abstract][Full Text] [Related]
30. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
Shelley MD; Wilt TJ; Court J; Coles B; Kynaston H; Mason MD
BJU Int; 2004 Mar; 93(4):485-90. PubMed ID: 15008714
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
32. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
33. Mitomycin C for the treatment of bladder cancer.
Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
Grimberg DC; Dudinec J; Shah A; Inman BA
Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
[TBL] [Abstract][Full Text] [Related]
35. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
36. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
Ferro M; Giuberti G; Zappavigna S; Perdonà S; Facchini G; Sperlongano P; Porto S; Di Lorenzo G; Buonerba C; Abbruzzese A; Altieri V; Caraglia M
Oncol Rep; 2012 Feb; 27(2):409-15. PubMed ID: 22052369
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis.
Lu JL; Xia QD; Lu YH; Liu Z; Zhou P; Hu HL; Wang SG
Cancer Med; 2020 Nov; 9(21):7800-7809. PubMed ID: 33040478
[TBL] [Abstract][Full Text] [Related]
38. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
[TBL] [Abstract][Full Text] [Related]
39. Intravesical electro-osmotic administration of mitomycin C.
Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
[TBL] [Abstract][Full Text] [Related]
40. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.
Zargar H; Aning J; Ischia J; So A; Black P
Nat Rev Urol; 2014 Apr; 11(4):220-30. PubMed ID: 24619373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
